Subscribe to RSS
DOI: 10.1055/s-0045-1811219
THERANOSTICS OF NEUROENDOCRINE TUMORS
Authors
Introduction: Theranostics is the association of targeted diagnostic imaging and therapeutics, having in common a single agent. 68Ga-DOTATE PET/CT, Octreoscan and 177Lu-Octreotate therapy have in common the radiolabeled somatostatin analogues. These techniques used in combination turn into the theranostics of neuroendocrine tumors. Objectives: To check demographic and clinical characteristics, toxicities and treatment response of patients with neuroendocrine tumors treated with 177Lu-Octreotate. Methods: This is a retrospective study. We reported a series of 43 consecutive patients with advanced neuroendocrine tumors submitted to 177Lu-Octreotate treatment. DOTATE-68Ga PET/CT or Octreoscan imaging were used for patient selection. Clinical and demographic characteristics were described according to their frequency (%) and means and medians were presented as indicated. Response assessments were performed based on subsequent 68Ga-DOTATE PET/CT images. Results: From November 2016 until February 2022, 43 patients were treated, being 23 women (53%) and 20 men (47%). Mean age was 57,4 years old (25-81). Most common primary sites were pancreas (60%), small intestine (16%) and liver (9%). Regarding Ki67 index, we could access it in 62% of the group (27/43), being most of them between 3-20% (78%). We obtained information about previous systemic treatment from 38 patients, and 36% of them (14/38) received previous treatment beyond somastotatin analogues. Most common previous systemic treatments were everolimus (50%), cisplatin/etoposide (35%), capecitabine/temozolamide (21%) and capecitabine/oxaliplatin (21%). Mean time from diagnosis to 177Lu-Octreotate treatment was 4.5 years (1-22 years). We could evaluate response in 27 patients and 85% (23/27) had disease control (stable disease, partial or complete response). None of the patients in this series presented grade 3-4 toxicities. Conclusions: The theranostics in neuroendocrine tumors allowed good patient outcomes and low toxicity.
No conflict of interest has been declared by the author(s).
Contato:
Publication History
Article published online:
03 November 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Thomás Giollo Rivelli, Tiago Kenji Takahashi, Dalton Alexandre dos Anjos, Renata Fockink dos Anjos, Bianca Mendes Carnevalli, Manuel Santos Cruz, Murilo Cazellato Pacheco de Mello, Gustavo Henrique Munhoz Piotto, Natalia Moreno Perez Fraile, Denyei Nakazato, Anezka Carvalho Rubin de Celis Ferrari, Simone Klug Loose, Renata Arakelian. THERANOSTICS OF NEUROENDOCRINE TUMORS. Brazilian Journal of Oncology 2022; 18.
DOI: 10.1055/s-0045-1811219